Clinical Trial Update: TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 study is recruiting to evaluate the combination of transarterial chemoembolization (TACE) with camrelizumab and apatinib in patients with unresectable…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Guohui Xu | Conditions: Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization | Phase 3 | Status: RECRUITING